ערך בספרים למניה: BeyondSpring (BYSI)

The dynamics of capital per share demonstrate the evolution of BeyondSpring Inc. (BYSI) assets in its drive to expand markets for neutropenia drugs. The value of -0.86 determines the latest valuation metric. Stability is ensured by the strong pricing power of plinabulin, while structural flexibility is maintained through the full outsourcing of manufacturing and clinical trials.

Book value per share reflects the portion of equity attributable to a single security, allowing for an assessment of the business's intrinsic value net of all liabilities. By analyzing the historical book value per share chart, investors determine the asset's margin of safety, which is critical for BeyondSpring Inc. (BYSI) due to stringent government price regulations on pharmaceuticals in China.